Clinical immunotoxicity of therapeutic proteins

Bibliography

• Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008;7(1):21-39
   PubMed Web of Science ®Google Scholar
• Dempster AM. Nonclinical safety evaluation of biotechnologically derived pharmaceuticals. Biotechnol Annu Rev 2000;5:221-58
   PubMedGoogle Scholar
• Cavagnaro JA. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nat Rev Drug Discov 2002;1(6):469-75
   PubMed Web of Science ®Google Scholar
• Brennan FR, Shaw L, Wing MG, et al. Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges. Mol Biotechnol 2004;27(1):59-74
   PubMed Web of Science ®Google Scholar
• Chapman K, Pullen N, Graham M, et al. Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat Rev Drug Discov 2007;6(2):120-6
   PubMed Web of Science ®Google Scholar
• Clarke J, Leach W, Pippig S, et al. Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody. Regul Toxicol Pharmacol 2004;40(3):219-26
   PubMed Web of Science ®Google Scholar
• Descotes J. Methods of evaluating immunotoxicity. Expert Opin Drug Metab Toxicol 2006;2(2):249-59
   PubMed Web of Science ®Google Scholar
• Luster MI, Ackermann MF, Germolec DR, et al. Perturbations of the immune system by xenobiotics. Environ Health Perspect 1989;81(5):157-62
   PubMed Web of Science ®Google Scholar
• Descotes J. Definition, history, and scope of immunotoxicology. In: immunotoxicology of drugs and chemicals. An experimental and clinical approach. volume1 principles and methods of immunotoxicology. Descotes J, edition. Elsevier Science, Amsterdam; 2004. p. 1-18
   Google Scholar
• Vos JF. Immune suppression as related to toxicology. CRC Crit Rev Toxicol 1977;5(1):67-101
   PubMed Web of Science ®Google Scholar
• Ich harmonized tripartite guideline S8: immunotoxicity studies for pharmaceuticals 2005 Document. Available from: http://www.ich.org/LOB/media/MEDIA1706.pdf
   Google Scholar
• Meylers L. Cytostatic drugs. In: Side-Effects of Drugs, 2nd edition. Meylers L, edition. Excerpta Medica, Amsterdam; 1966. p. 472-94
   Google Scholar
• Descotes J. Health consequences of immunotoxic effects. In: immunotoxicology of drugs and chemicals. An experimental and clinical approach. Volume1 principles and methods of immunotoxicology, edition. Descotes J Elsevier Science, Amsterdam 2004. p. 55-126
   Google Scholar
• Lin J, Ziring D, Desai S, et al. TNF alpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008;126(1):13-30
   PubMed Web of Science ®Google Scholar
• Rychly DJ, Dipiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005;25(9):1181-92
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295(19):2275-85
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Listing J. Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol 2006;20(6):1181-95
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345(15):1098-104
   PubMed Web of Science ®Google Scholar
• Theis VS, Rhodes JM. Minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 20087(1):19-30
   Google Scholar
• Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2(6):561-72
   PubMed Web of Science ®Google Scholar
• Mohan VP, Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001;69(3):1847-55
   PubMed Web of Science ®Google Scholar
• Botha T, ryffel B. Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol 2003;171(6):3110-8
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Samonis G, Boumpas DT, et al. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008;83(2):181-94
   PubMed Web of Science ®Google Scholar
• Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007;52(6):1481-4
   PubMed Web of Science ®Google Scholar
• Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003;48(2):319-24
   PubMed Web of Science ®Google Scholar
• Rafailidis PI, Kakisi OK, Vardakas K, et al. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 2007;109(11):2182-9
   PubMed Web of Science ®Google Scholar
• Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31(6):456-73
   PubMed Web of Science ®Google Scholar
• Fraser G, Smith CA, Imrie K, et al. The Hematology Disease Site Group of cancer care ontario's program in evidence-based care. Alemtuzumab in chronic lymphocytic leukemia Curr Oncol 2007;14(3):96-109
   PubMedGoogle Scholar
• Vial T, Descotes J. Clinical adverse effects of cytokines. In: Cytokines in Human Health: Immunotoxicology, Pathology, and Therapeutic Applications, House RV, Descotes J, editors. Humana Press, Totowa NJ 2007. p. 319-48
   Google Scholar
• Berger JR. Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis 2006;65(Suppl 3):48-53
   Web of Science ®Google Scholar
• Stüve O. The effects of natalizumab on the innate and adaptive immune system in the central nervous system. J Neurol Sci 2008; [Epub ahead of print]
   Google Scholar
• Vial T, Descotes J. Immunosuppressive drugs and cancer. Toxicol 2003;185(3):229-40
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005;64(7):1421-6
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56(9):2886-95
   PubMed Web of Science ®Google Scholar
• Carmona L, Descalzo MA, Perez-Pampin E, et al and the Biobadaser and Emecar Groups. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007;66(7):880-5
   PubMed Web of Science ®Google Scholar
• Askling J, Bongartz T. Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008;20(3):334-9
   PubMed Web of Science ®Google Scholar
• Descotes J. Adverse consequences of chemical immunomodulation. Clin Res Pract Drug Regul Affairs 1985;3:45-52
   Google Scholar
• Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355(10):1018-28
   PubMed Web of Science ®Google Scholar
• Descotes J, Vial T. Flu-like syndromes and cytokines. In: Cytokines in Human Health: Immunotoxicology, Pathology, and Therapeutic Applications, House RV, Descotes J, editors. Humana Press, Totowa NJ 2007. p. 193-204
   Google Scholar
• Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med 2008;26(6):711-5
   PubMed Web of Science ®Google Scholar
• Wing M. Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction. J Immunotoxicol 2008;5(1):11-5
   PubMed Web of Science ®Google Scholar
• Van Der Kolk LE, Grillo-Lopez AJ, Baars JW, et al. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115(4):807-11
   PubMed Web of Science ®Google Scholar
• Sgro C. Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Toxicol 1995;105(1):23-9
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Bannink M, Van Gool AR, et al. Side effects of interferon-alpha therapy. Pharm World Sci 2005;27(6):423-31
   PubMed Web of Science ®Google Scholar
• Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008;13(6):725-32
   PubMed Web of Science ®Google Scholar
• Miossec P. Cytokine-induced autoimmune disorders. Drug Safi 1997;17(2):93-104
   PubMed Web of Science ®Google Scholar
• Monzani F, Caraccio N, Dardano A, et al. Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med 2004;3(4):199-210
   PubMed Web of Science ®Google Scholar
• Selmi C, Lleo A, Zuin M, Podda M, et al. Interferon alpha and its contribution to autoimmunity. Curr Opin Investig Drugs 2006;7(5):451-6
   PubMed Web of Science ®Google Scholar
• Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008;37(6):381-7
   PubMed Web of Science ®Google Scholar
• Zukiwski AA, David CL, Coan J, et al. Increased incidence of hypersensitivity to iodine-containing radiographic contrast media after interleukin-2 administration. Cancer 1990;65(7):1521-4
   PubMed Web of Science ®Google Scholar
• Choyke PL, Miller DL, Lotze MT, et al. Delayed reactions to contrast media after interleukin-2 immunotherapy. Radiology 1992;183(1):111-4
   PubMed Web of Science ®Google Scholar
• Shulman KL, Thompson JA, Benyunes MC, et al. Adverse reactions to intravenous contrast media in patients with interleukin-2. J Immunother 1993;13(3):208-12.
   Web of Science ®Google Scholar
• Descotes J. Immunomodulating agents and hepatic drug-metabolizing enzymes. Drug Metab Rev 1985;16(1-2):175-84
   PubMed Web of Science ®Google Scholar
• Renton KW. Cytokines and pharmacokinetic drug interactions. In: Cytokines in Human Health: Immunotoxicology, Pathology, and Therapeutic Applications, House RV, Descotes J, editors. Humana Press, Totowa NJ 2007. p. 275-98
   Google Scholar
• US FDA Guidance on immunotoxicology evaluation of new investigational drugs (2002) document. Available from: http://www.fda.gov/cder/guidance/4945fnl.pdf
   Google Scholar
• Emea guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins 2007 document. Available from: http://www.emea.europa.eu/pdfs/human/biosimilar/1432706en.pdf
   Google Scholar
• Jakobovits A, Amado RG, Yang X, et al. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 2007;25(10):1134-43
   PubMed Web of Science ®Google Scholar
• Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 2005;20(Suppl 6):3-9
   Web of Science ®Google Scholar
• Mukovozov I, Sabljic T, Hortelano G, et al. Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins. Thromb Haemost 2008;99(5):874-82
   PubMed Web of Science ®Google Scholar
• De Groot AS, SCOTT DW. Immunogenicity of protein therapeutics. Trends Immunol 2007;28(11):482-90
   PubMed Web of Science ®Google Scholar
• Hermeling S, Crommelin DJ, Schellekens H, et al. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 2004;21(6):897-903
   PubMed Web of Science ®Google Scholar
• Veronese FM, Mero A. The impact of PEGylation on biological therapies. Bio Drugs 2008;22(5):315-29
   Google Scholar
• Rosenberg S. Effects of protein aggregates: an immunologic perspective. AAPS J 2006;8(3):E501-7
   PubMed Web of Science ®Google Scholar
• Van DE Weert M, Jorgensen L, Horn Moeller E, et al. Factors of importance for a successful delivery system for proteins. Expert Opin Drug Deliv 2005;2(6):1029-37
   PubMed Web of Science ®Google Scholar
• Koren E, Smith HW, Shores E, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 2008;333(1-2):1-9
   PubMed Web of Science ®Google Scholar
• Gupta S, Indelicato SR, Jethwa V, et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 2007;321(1-2):1-18
   PubMed Web of Science ®Google Scholar
• Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 2007;68(13):977-84
   PubMed Web of Science ®Google Scholar
• Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001;98(12):3241-8
   PubMed Web of Science ®Google Scholar
• Mcdougall IC. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol Dial Transplant 2005;20(Suppl 4):9-15
   Web of Science ®Google Scholar
• Mcdougall IC. Epoetin-induced pure red cell aplasia: diagnosis and treatment. Curr Opin Nephrol Hypertens 2007;16(6):585-8
   PubMed Web of Science ®Google Scholar
• Corona T, Leon C, Ostrosky-Zeichner L. Severe anaphylaxis with recombinant interferon beta. Neurology 1999;52(2):425
   PubMed Web of Science ®Google Scholar
• Shopnick RI, Kazemi M, Brettler DB, et al. Anaphylaxis after treatment with recombinant factor VIII. Transfusion 1996;36(4):358-61
   PubMed Web of Science ®Google Scholar
• Castéra V, Dutour-Meyer A, Koeppel M, et al. Systemic allergy to human insulin and its rapid and long acting analogs: successful treatment by continuous subcutaneous insulin lispro infusion. Diabetes Metab 2005;31(4):391-400
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008;358(11):1109-17
   PubMed Web of Science ®Google Scholar
• Chávez-López MA, Delgado-Villafaña J, Gallaga A, et al. Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis. Allergol Immunopathol (Madr) 2005;33(5): 291-2
   PubMedGoogle Scholar
• Stallmach A, Giese T, Schmidt C, et al. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. Eur J Gastroenterol Hepatol 2004;16(6):627-30
   PubMed Web of Science ®Google Scholar
• Baudouin V, Crusiaux A, Haddad E, et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation 2003;76(3):459-63
   PubMed Web of Science ®Google Scholar
• Pharand C, Palisaitis DA, Hamel D. potential anaphylactic shock with abciximab readministration. Pharmacother 2002;22(3):380-3
   PubMed Web of Science ®Google Scholar
• Riegert-Johnson DL, Godfrey JA, Myers JL, et al. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis 2002;8(3):186-91
   PubMed Web of Science ®Google Scholar
• Gourley I, Descotes J. Bridging immunotoxicology to clinical drug development. In: Immunotoxicology Strategies for Pharmaceutical Safety Assessment. Herzyk D, Bussiere J, Editors. John Wiley & Sons New York. p. 375-84
   Google Scholar
• HESI ITC Workshop on Immunomodulators and Clinical Immunotoxicology 2007 document. Available from: http://www.hesiglobal.org/Committees/TechnicalCommittees/Immunotox/HESIImmunotoxWkshop.htm
   Google Scholar